|Day's Range||62.50 - 62.90|
|52 Week Range||57.18 - 66.80|
|PE Ratio (TTM)||39.88|
|Earnings Date||Jul 28, 2017|
|Dividend & Yield||1.88 (3.00%)|
|1y Target Est||69.70|
Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a mechanism tumors use to hide from the immune system allowing it to recognize and attack the cancer, won accelerated U.S. approval last August for these patients based on its ability to shrink tumors. As a condition of the accelerated approval, Merck was required to conduct a trial to demonstrate superiority over standard treatment and verify the clinical benefit of Keytruda in this patient population.
Merck , known as MSD outside the United States and Canada, today announced that the pivotal phase 3 KEYNOTE-040 trial investigating KEYTRUDA® , the company’s anti-PD-1 therapy, in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma did not meet its pre-specified primary endpoint of overall survival . The safety profile observed in KEYNOTE-040 was consistent ...
Pharmaceutical giants Bristol-Myers Squibb Co (NYSE: BMY ) and Merck & Co., Inc. (NYSE: MRK ) both release their second quarter earnings reports this week. According to BMO Capital, investors should be ...